Back to Results
First PageMeta Content
Pharmaceutical sciences / Pharmaceuticals policy / Pharmacology / Drug safety / Clinical Trials Directive / Pharmacovigilance / Clinical trial / Good Clinical Practice / Adverse event / Clinical research / Research / Pharmaceutical industry


Comment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health on
Add to Reading List

Document Date: 2013-10-09 09:33:27

Open Document

File Size: 128,90 KB

Share Result on Facebook

Company

Clinical Trials Facilitation Group / /

Continent

Europe / /

Country

Germany / /

Facility

EC The Federal Institute / Federal Institute / Paul Ehrlich Institute / /

IndustryTerm

trial protocols / authorisation applications / pharmaceuticals / investigational medicinal product / possible solutions / investigational medicinal products / pharmaceutical industry / medicinal products / health insurance / /

Organization

European Agency for the Evaluation of Medicinal Products / European Union / European Parliament / NCA National Competent Authority / national licensing authority / Ministry of Health / OECD / Ethics Committee / Paul Ehrlich Institute / Federal Institute for Drugs and Medical Devices / /

Position

head / Detective / legislator / /

Product

TeGenero / /

ProgrammingLanguage

EC / /

Technology

trial protocols / pdf / /

URL

http /

SocialTag